Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 6/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PEPD | P12955 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352377 | 1.00 | GRM2 (0.44) | GRM2CNR1CNR2HSD11B1CYP1A2 | |
| SCHEMBL19815410 | 1.00 | GRM2 (0.44) | GRM2CNR1CNR2HSD11B1CYP1A2 | |
| SCHEMBL16239057 | 0.94 | GRM2 (0.46) | GRM2CNR1CNR2HSD11B1CYP1A2 | |
| SCHEMBL3712881 | 0.94 | GRM2 (0.46) | GRM2CNR1CNR2HSD11B1CYP1A2 | |
| SCHEMBL9108702 | 0.92 | GRM2 (0.53) | GRM2CNR1CNR2HSD11B1CYP1A2 | |
| SCHEMBL9108708 | 0.92 | GRM2 (0.53) | GRM2CNR1CNR2HSD11B1CYP1A2 | |
| SCHEMBL2569370 | 0.88 | HSD11B1 (0.58) | GRM2CNR1CNR2HSD11B1CYP1A2 | |
| SCHEMBL2569369 | 0.88 | HSD11B1 (0.58) | GRM2CNR1CNR2HSD11B1CYP1A2 | |
| SCHEMBL3710751 | 0.83 | HSD11B1 (0.53) | GRM2CNR1CNR2HSD11B1KDM4E | |
| SCHEMBL3710748 | 0.83 | HSD11B1 (0.53) | GRM2CNR1CNR2HSD11B1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ABAC Therapeutics, S.L. (ES) | 2021-02-16 | — | — | US | disclosed |
| EP-3490984-B1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | Abac Therapeutics Sl (ES) | 2020-09-09 | — | — | EP | disclosed |
| US-20190177272-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ABAC Therapeutics, S.L. (ES) | 2019-06-13 | — | — | US | disclosed |
| EP-3490984-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | Abac Therapeutics, S.L (ES) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018178397-A1 | N-ALKYLATED AMINO ACIDS AND OLIGOPEPTIDES, USES THEREOF AND METHODS FOR PROVIDING THEM. | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2018-10-04 | — | — | WO | disclosed |
| WO-2018020004-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ABAC THERAPEUTICS, S.L (ES) | 2018-02-01 | — | — | WO | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8618152-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| EP-1636208-B1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMA (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-22 | — | — | US | disclosed |
| EP-1636208-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050090450-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS, INCORPORATED | 2005-04-28 | — | — | US | disclosed |
| WO-2004092162-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2004-10-28 | — | — | WO | disclosed |
| US-5468876-A | Intermediates for the stereoconservative synthesis of 1-substituted (S)-and (R)-2-aminomethylpyrrolidines | AKTIEBOLAGET ASTRA (SE) | 1995-11-21 | — | — | US | disclosed |
| US-5300660-A | Efficient stereoconservative synthesis of 1-substituted (S)- and (R)-2-aminomethylpyrrolidines and intermediates thereto | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1994-04-05 | — | — | US | disclosed |
| EP-0253785-B1 | EFFICIENT STEREOCONSERVATIVE SYNTHESES OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THEREIN | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0270596-A1 | A STEREOCONSERVATIVE SYNTHESIS OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THERETO | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1988-06-15 | — | — | EP | disclosed |
| EP-0253785-A1 | Efficient stereoconservative syntheses of 1-substituted (S)- and (R)-2-aminomethylpyrrolidines and intermediates therein | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1988-01-20 | — | — | EP | disclosed |
| WO-1987007271-A1 | A STEREOCONSERVATIVE SYNTHESIS OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THERETO | Astra Läkemedel Aktiebolag (SE) | 1987-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177272-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ATAD2, ATAD2B, ATAD5 | GRM2 3811/4885CNR1 3323/4885CNR2 2654/4885 |
| US-20050090450-A1 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | PRSS1, SERPINB1, SPINT2 | GRM2 4876/4885CNR1 3178/4885CNR2 4256/4885 |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | GRM2 392/4885CNR1 2/4885CNR2 1/4885 |
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ATAD2, ATAD2B, ATAD5 | GRM2 3811/4885CNR1 3323/4885CNR2 2654/4885 |
| US-20090022688-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | GRM2 4876/4885CNR1 3073/4885CNR2 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.